|
|
|
|
|
|
|
|
|
|
"Conclusions:Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools should allow ineffective agents to be discarded and promising agents to undergo further investigation."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.